Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Update

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the recipient of a significant drop in short interest in June. As of June 15th, there was short interest totaling 33,404 shares, a drop of 85.2% from the May 31st total of 225,674 shares. Approximately 6.0% of the company’s stock are sold short. Based on an average daily volume of 313,931 shares, the days-to-cover ratio is presently 0.1 days.

Shuttle Pharmaceuticals Stock Performance

NASDAQ:SHPH traded up $0.24 during mid-day trading on Friday, hitting $4.02. The stock had a trading volume of 31,511,150 shares, compared to its average volume of 732,469. Shuttle Pharmaceuticals has a twelve month low of $3.16 and a twelve month high of $55.90. The stock has a market cap of $2.56 million, a price-to-earnings ratio of -0.08 and a beta of 0.18. The company’s 50 day simple moving average is $6.34 and its 200 day simple moving average is $11.10.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.60 earnings per share for the quarter.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in SHPH. Geode Capital Management LLC acquired a new stake in Shuttle Pharmaceuticals during the 4th quarter valued at $26,000. Boothbay Fund Management LLC acquired a new position in shares of Shuttle Pharmaceuticals in the fourth quarter valued at $37,000. Ikarian Capital LLC acquired a new position in shares of Shuttle Pharmaceuticals in the fourth quarter valued at $124,000. Finally, Connective Capital Management LLC bought a new position in shares of Shuttle Pharmaceuticals in the third quarter valued at about $357,000. Institutional investors own 4.58% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Shuttle Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research note on Monday, June 15th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Shuttle Pharmaceuticals has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .